ReviewEuropean respiratory review : an official journal of the European Respiratory Society2011
Looking to the future: a new decade of pulmonary arterial hypertension therapy.
Review in European respiratory review : an official journal of the European Respiratory Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Trial
- Review
- Dan-Shen-Yin Granules Prevent Hypoxia-Induced Pulmonary HypertensionFrontiers in pharmacology · 2022Article
- MicroRNA-221 promotes proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs) by targeting tissue inhibitor of metalloproteinases-3 (TIMP3).Cardiovascular diagnosis and therapy · 2020Article
- Effectiveness and safety of exercise training and rehabilitation in pulmonary hypertension: a systematic review and meta-analysis.Journal of thoracic disease · 2020Article
- Pulmonary hypertension: From an orphan disease to a global epidemic.Global cardiology science & practice · 2020Review
- Characteristics of circular RNA expression in lung tissues from mice with hypoxia‑induced pulmonary hypertension.International journal of molecular medicine · 2018Article
- Role of Krüppel-like factor 4 in cigarette smoke-induced pulmonary vascular remodeling.American journal of translational research · 2018Article
- Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding.BioMed research international · 2018Article
- Prediction of target genes for miR-140-5p in pulmonary arterial hypertension using bioinformatics methods.FEBS open bio · 2017Article
- Microarray profiling of long non-coding RNAs associated with idiopathic pulmonary arterial hypertension.Experimental and therapeutic medicine · 2017Article
- Article
- Article
- Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.Acta pharmacologica Sinica · 2016Article
- Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.Biomarker insights · 2016Review
- The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients.BMC health services research · 2014Article
- The role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series).Pulmonary circulation · 2014Review
- Trends in pulmonary hypertension mortality and morbidity.Pulmonary medicine · 2014Article
- The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.Circulation · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary arterial hypertension (PAH) is a severe and debilitating disease characterised by vascular proliferation and remodelling of the small pulmonary arteries, leading to a progressive increase in pulmonary vascular resistance, increased afterload on the right ventricle and, ultimately, right heart failure. Although there is no "cure" for PAH, the availability of targeted therapies over the past decade has led to major advances in the management of PAH, reflected in improvements in survival in the modern treatment era. However, despite this, disease progression is inevitable in the majority of patients with PAH and overall the long-term prognosis, although improved, remains poor. There is a clear and urgent need for new therapeutic options, either through the development of improved drugs that act on targets established by existing PAH-specific therapies, or of agents targeting novel pathogenic pathways not addressed by currently available therapies. A number of such new agents that have shown promise in experimental models and preliminary human studies are discussed in this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.